ERBB2 and neoplasm: By binding to HER2 on the surface of tumor cells, trastuzumab blocks the binding of human epidermal growth factor to HER2, thereby affecting the transmission of tumor cell growth signals for controlled tumor proliferation and delayed recurrence and metastasis (34, 35).